Todd C. Davis - Mar 25, 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Executive Officer, Director
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis
Stock symbol
LGND
Transactions as of
Mar 25, 2024
Transactions value $
$919,147
Form type
4
Date filed
3/27/2024, 05:47 PM
Previous filing
Feb 29, 2024
Next filing
Jun 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $344K +7.45K +7.15% $46.20 112K Mar 25, 2024 Direct
transaction LGND Common Stock Options Exercise $192K +2.86K +2.56% $67.24 114K Mar 25, 2024 Direct
transaction LGND Common Stock Options Exercise $148K +2.16K +1.88% $68.51 117K Mar 25, 2024 Direct
transaction LGND Common Stock Options Exercise $235K +3.56K +3.05% $66.19 120K Mar 25, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -7.45K -100% $0.00* 0 Mar 25, 2024 Common Stock 7.45K $46.20 Direct F1
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -3.56K -100% $0.00* 0 Mar 25, 2024 Common Stock 3.56K $66.19 Direct F2
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -2.86K -100% $0.00* 0 Mar 25, 2024 Common Stock 2.86K $67.24 Direct F3
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -2.16K -100% $0.00* 0 Mar 25, 2024 Common Stock 2.16K $68.51 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Option was previously reported as a Grant of 4,340 shares at an exercise price of $79.29 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer, then vested in full on June 10, 2023.
F2 This Option was previously reported as a Grant of 4,071 shares, which vested in full on June 9, 2020, at an exercise price of $113.59 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
F3 This Option was previously reported as a Grant of 3,269 shares, which vested in full on June 4, 2022, at an exercise price of $115.39 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
F4 This Option was previously reported as a Grant of 2,468 shares, which vested in full on June 4, 2021, at an exercise price of $117.58 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.